dc.creatorCalabrese, Graciela Cristina
dc.creatorAlberto, Maria Fabiana
dc.creatorTubio, Maria Rosario
dc.creatorMarani, Mariela Mirta
dc.creatorFernández De Recondo, Marta E.
dc.creatorLazzari, María Ángela
dc.creatorRecondo, Eduardo F.
dc.date.accessioned2018-12-13T19:02:42Z
dc.date.accessioned2022-10-15T13:42:22Z
dc.date.available2018-12-13T19:02:42Z
dc.date.available2022-10-15T13:42:22Z
dc.date.created2018-12-13T19:02:42Z
dc.date.issued2004-01
dc.identifierCalabrese, Graciela Cristina; Alberto, Maria Fabiana; Tubio, Maria Rosario; Marani, Mariela Mirta; Fernández De Recondo, Marta E.; et al.; A small fraction of dermatan sulfate with significantly increased anticoagulant activity was selected by interaction with the first complement protein; Pergamon-Elsevier Science Ltd; Thrombosis Research; 113; 3-4; 1-2004; 243-250
dc.identifier0049-3848
dc.identifierhttp://hdl.handle.net/11336/66438
dc.identifierCONICET Digital
dc.identifierCONICET
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4392634
dc.description.abstractDermatan sulfate (DS) is a member of the family of structurally complex, sulfated, linear heteropolysaccharides called glycosaminoglycans (GAGs). It has a similar structure to heparin and heparan sulfate (HS), but with acetylgalactosamine replacing glucosamine, and the uronic acid moiety, mainly iduronic, joined 1→3 to the hexosamine. We are studying the relationships between structure and activities of dermatan sulfate, in particular those associated with the thrombin inhibition mediated by heparin cofactor II (HCII). As we have demonstrated with heparin, a small fraction of dermatan sulfate was isolated by precipitation with the first component of the complement system, under very specific conditions of low ionic strength, and the presence of calcium ions. The sulfate content and the anticoagulant activity of the dermatan sulfate fraction isolated in the precipitate were three and four times greater respectively than the starting material. Our in vivo studies showed that this fraction has threefold higher thrombolytic activity than the DS. All these results suggest that this fraction could be used as a therapeutic agent for thrombi dissolution. © 2004 Elsevier Ltd. All rights reserved.
dc.languageeng
dc.publisherPergamon-Elsevier Science Ltd
dc.relationinfo:eu-repo/semantics/altIdentifier/doi/https://doi.org/10.1016/j.thromres.2004.01.014
dc.relationinfo:eu-repo/semantics/altIdentifier/url/https://www.sciencedirect.com/science/article/pii/S0049384804000143
dc.rightshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/
dc.rightsinfo:eu-repo/semantics/restrictedAccess
dc.subjectAntithrombin
dc.subjectAt
dc.subjectC1
dc.subjectComplement System
dc.subjectCon A
dc.subjectConcanavalin A
dc.subjectDermatan Sulfate
dc.subjectDs
dc.subjectFree Dermatan Sulfate
dc.subjectFree Ds
dc.subjectGag
dc.subjectGlycosaminoglycan
dc.subjectHeparin Cofactor Ii
dc.subjectHs
dc.subjectMolecular Interactions
dc.subjectThe First Protein Complex Of the Complement System
dc.titleA small fraction of dermatan sulfate with significantly increased anticoagulant activity was selected by interaction with the first complement protein
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:ar-repo/semantics/artículo
dc.typeinfo:eu-repo/semantics/publishedVersion


Este ítem pertenece a la siguiente institución